Loading
Heart Failure Treatment and Management / Diabetes Treatment and Management · Journal article
Exploration of Cardiology · July 6, 2026
A consensus or society position rather than new primary data.
This structured narrative review synthesizes evidence from randomized controlled trials, meta-analyses, and mechanistic studies to reframe SGLT2 inhibitors as systemic metabolic stress modulators with benefits across the cardiovascular-renal-metabolic spectrum. The evidence supports their use as foundational disease-modifying therapies in heart failure, chronic kidney disease, and metabolic dysfunction, with effects mediated by tubuloglomerular feedback restoration, enhanced cardiac energy efficiency, and anti-inflammatory signaling.
Structured narrative review. Published clinical trials, meta-analyses, observational cohorts, guidelines, and translational studies investigating SGLT2 inhibitors in type 2 diabetes, heart failure, chronic kidney disease, and metabolic dysfunction.. Intervention: Sodium–glucose cotransporter 2 inhibitors (SGLT2i).
SGLT2 inhibitors reduce hospitalization for heart failure in both diabetic and non-diabetic populations SGLT2 inhibitors delay chronic kidney disease progression across CKD stages SGLT2 inhibitors improve major cardiovascular outcomes beyond glycemic control
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians in cardiology, nephrology, and endocrinology should consider SGLT2 inhibitors as foundational disease-modifying agents across cardiovascular-renal-metabolic conditions, with benefits extending beyond glucose lowering. Future implementation should incorporate precision-based biomarker-guided patient selection and rational combination pharmacotherapy.
A structured narrative review synthesizing evidence from RCTs, meta-analyses, and mechanistic studies to establish a conceptual framework and therapeutic recommendations for SGLT2 inhibitor use across cardiovascular-renal-metabolic conditions.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians in cardiology, nephrology, and endocrinology should consider SGLT2 inhibitors as foundational disease-modifying agents across cardiovascular-renal-metabolic conditions, with benefits extending beyond glucose lowering. Future implementation should incorporate precision-based biomarker-guided patient selection and rational combination pharmacotherapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as glucose-lowering therapies for type 2 diabetes mellitus. However, robust clinical evidence has demonstrated substantial cardiovascular and renal protective effects that extend beyond glycemic control. Emerging data highlight their systemic influence across the cardiovascular–renal–metabolic (CRM) continuum, a conceptual framework describing the shared pathophysiological links between metabolic dysfunction, heart failure (HF), and chronic kidney disease (CKD). Despite the rapid expansion of clinical and mechanistic evidence, the integration of these insights into coordinated therapeutic implementation across cardiology, nephrology, and endocrinology remains incompletely synthesized. This structured narrative review synthesized evidence from PubMed/MEDLINE, Embase, and Google Scholar to identify relevant studies published between January 2016 and December 2025. Emphasis was placed on randomized controlled trials, meta-analyses, large observational cohorts, guideline documents, and translational mechanistic investigations evaluating pharmacologic mechanisms, clinical efficacy, and multidisciplinary applications of SGLT2i across CRM conditions. Cardiovascular and renal outcome trials consistently show that SGLT2i reduce hospitalization for heart failure, delay CKD progression, and improve major cardiovascular outcomes in both diabetic and non-diabetic populations. Mechanistically, these agents restore tubuloglomerular feedback, enhance cardiac energy efficiency through increased ketone utilization, attenuate inflammatory and profibrotic signaling pathways, and improve mitochondrial bioenergetics. These multisystem effects contribute to therapeutic benefits across HF phenotypes and CKD stages while also improving metabolic parameters such as adiposity, blood pressure, and hepatic steatosis. Collectively, current evidence supports SGLT2i as foundational disease-modifying therapies across the CRM spectrum. Future investigations should prioritize precision-based treatment approaches, biomarker-guided patient selection, and rational combination pharmacotherapy to further optimize outcomes across interconnected cardiovascular, renal, and metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.